Standard BioTools Swaps Mass Cytometry Buyer: Element Biosystems Replaces Multiplex Bio in $5.5M Deal
LAB sits 20% above its 52-week low of $0.625.
Summary
Standard BioTools replaced its Mass Cytometry buyer with Element Biosystems in a $5.5 million cash deal that improves net cash by ~$15 million versus the prior Multiplex Bio agreement. The Element purchase agreement includes a $1.0 million termination fee payable by Standard BioTools under specified circumstances, plus up to $250,000 expense reimbursement if closing is delayed past December 31, 2026 or March 31, 2027.
Updated with an SEC 425 filing · What changed
Updates
· SEC 425 — Element purchase agreement includes a $1.0 million termination fee payable by Standard BioTools under specified circumstances, plus up to $250,000 expense reimbursement if closing is delayed past December 31, 2026 or March 31, 2027.
Key Events · M&A and Partnerships · LAB
-
Updated · · SEC 425
Closing Conditions, Timeline, and Termination Fee
The Element transaction is expected to close by the end of 2026, substantially concurrently with the Treeline Biosciences merger, subject to stockholder approval and customary closing conditions. The Element purchase agreement includes a $1.0 million termination fee payable by Standard BioTools under specified circumstances, plus up to $250,000 expense reimbursement if closing is delayed past December 31, 2026 or March 31, 2027.
-
New Buyer for Mass Cytometry Business
Standard BioTools terminated its Multiplex Bio purchase agreement and signed a new Share and Asset Purchase Agreement with Element Biosystems, LLC, a GMT Venture subsidiary, for $5.5 million in cash.
-
Net Cash Improvement of ~$15M
The Element deal eliminates a $10 million working capital loan obligation required under the Multiplex Bio agreement, increasing net cash position by approximately $15 million after termination and transaction fees.
-
Termination Fee Paid to Multiplex Bio
Standard BioTools paid a $1.5 million termination fee to Multiplex Bio, with GMT Venture contributing $1.0 million on the Company's behalf.
Analysis · LAB · Life Sciences
Standard BioTools terminated its July 28 agreement to sell its Mass Cytometry business to Multiplex Bio and signed a new deal with Element Biosystems, a GMT Venture subsidiary, for $5.5 million in cash. The new agreement eliminates a $10 million working capital loan obligation that existed under the Multiplex Bio deal, boosting the company's net cash position by approximately $15 million after fees. This is a material improvement in deal terms driven by a superior unsolicited proposal from GMT Venture, and it directly affects the cash available to the combined company in the pending Treeline Biosciences reverse merger. The Element purchase agreement includes a $1.0 million termination fee payable by Standard BioTools under specified circumstances, plus up to $250,000 expense reimbursement if closing is delayed past December 31, 2026 or March 31, 2027.
How filings like this one have moved
In the 30 days to Oct 3, 2026, 36.6% of the 1045 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.62%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LAB was trading at $0.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $290.7M. The 52-week trading range was $0.63 to $1.72. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.